Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT05912972
Recruiting Observational

Development and Management of Registry in Patients With Gynecologic Cancer in Korea

NCT05912972 · tracked via the Priya Life Science South Korea tracker
Sponsor
Asan Medical Center
Phase
Observational
Started
2022-10-21
Last updated
2023-06-22

Condition(s) studied

Cervical CancerEndometrial CancerOvarian CancerFallopian Tube CancerPeritoneal Cancer

Investigational drug(s) / intervention(s)

Patient registry

Patient registry: Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures

Study summary

The goal of this observational study is to identify and analyze the characteristics, treatment trends, prognostic factors and survival prognosis of Korean gynecologic cancer patients. Ultimately, the final goal is to contribute to the development of safe surgical methods and treatment for gynecologic cancer to improve survival rates.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Female patients 18 years or older * Written informed consent (prospective cohort) * Confirmed diagnosis of cervical cancer, endometrial cancer or ovarian cancer Exclusion Criteria: * Unconfirmed diagnosis of cervical cancer, endometrial cancer or ovarian cancer

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center Seoul South Korea Recruiting

More Asan Medical Center trials in South Korea

Brain Glioma Registry Combining Clinical and Imaging Information Recruiting
FMT With Nivolumab in Patients With Advanced Solid Cancers Who Have Progressed During Anti-PD-(L)1 Therapy Recruiting
Asan Aorta and Peripheral Registry Recruiting
A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML. Enrolling by invitation
Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer Starting soon

Other trials for the same condition

First in Human Study of TORL-1-23 in Participants With Advanced Cancer Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer Recruiting
Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer Starting soon
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers Recruiting
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05912972 on ClinicalTrials.gov ↗ ← All trials in South Korea